Host: Pavani Chalasani, MD, MPH


Guest: Kevin Kalinsky MD, MS




CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.

свернуть